Sandy Spring Bank’s Vir Biotechnology VIR Stock Holding History

Sandy Spring Bank’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,000	Closed	-$10.1K	–	1340
2024 Q1	$10.1K	Buy	+1,000	New	+$10.2K	﹤0.01%	850

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Sandy Spring Bank's VIR Position: Q2 2024 in Review

Sandy Spring Bank sold out of Vir Biotechnology (VIR) in Q2 2024, closing a stake of 1,000 shares — an estimated $10.1K sold.

Sandy Spring Bank first reported a position in VIR in Q1 2024 and held it in 1 quarter. The position peaked at $10.1K in Q1 2024. 215 funds tracked by Wall St. Rank hold VIR as of Q2 2024.

Sandy Spring Bank reported no remaining Vir Biotechnology position as of Q2 2024 after selling out during the quarter.
Sandy Spring Bank sold 1,000 Vir Biotechnology shares in Q2 2024, an estimated $10.1K.
Sandy Spring Bank first reported a position in Vir Biotechnology in Q1 2024 and held it in 1 quarter.
Sandy Spring Bank's Vir Biotechnology position peaked at $10.1K in Q1 2024.
215 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2024.

Based on Sandy Spring Bank's 13F filing for Q2 2024, filed 6 Aug 2024.